LAURUS LABS LTD
GenericsLAURUS LABS LTD is a generic drug manufacturer focused on Cardiovascular, Infectious Disease, Respiratory. Key products include EFAVIRENZ, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE.
LAURUS LABS LTD's Key Drugs
LAURUS LABS LTD's core commercial portfolio centers on SACUBITRIL AND VALSARTAN, EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, spanning Cardiovascular and Infectious Disease — its most strategically important drugs approved in the last 15 years.
Heart Failure
Human Immunodeficiency Virus
HIV-1 infection
HIV Infection
LAURUS LABS LTD's Recent FDA Approvals
New NDA/BLA approvals for LAURUS LABS LTD over the last two years — novel drugs only, excluding generics and label supplements.
LAURUS LABS LTD's Therapeutic Areas
LAURUS LABS LTD's approved drugs and pipeline span 4 therapeutic areas, led by Cardiovascular and Infectious Disease, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
LAURUS LABS LTD's Top Competitors
LAURUS LABS LTD's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and LEDERLE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
LAURUS LABS LTD Pipeline Snapshot
Active clinical trials for LAURUS LABS LTD across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • SACUBITRIL AND VALSARTAN leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (3)
Company Info
- First Approval
- 2018-08-27
- Latest
- 2026-08-11
- Applications
- 30